Strain Data Sheet
Data update: Aug 20, 2019
Health Report   PCR Protocol   Thawing Method
embryos / sperm >
  Mouse Marking
RBRC No. RBRC01709  
Type TransgeneCartagena  
Species Mus musculus  
Strain name B6.Cg-Tg(Mt1-RET)304Ina/B6  
Former Common name 304-B6 RET  
H-2 Haplotype No Data  
Background strain No Data  
 1 Appearance black  
Genotype a/a B/B C/C +/+  
 2 Appearance black with black skin (hyperpigmented skin)  
Genotype a/a B/B C/C Tg/+  
Strain development Developed by Masashi Kato, Nagoya University Graduate School of Medicine. The Mt1-RET transgene was injected into the fertilized eggs of (BALB/c x C57BL/6) x BALB/c mice. C57BL/6 and BALB/c mixed background.  
Strain description Mt1-Ret 304 transgenic mice. The mice express the human RET under the control of the mouse MT1 promoter/enhancer. This Mt1-RET 304 strain is a model of cutaneous melanosis, and develops benign tumors 100% on the skin. Of these tumors, 65% transform to malignant tumors in ten to twelve months after the birth. Tg homozygous mice are embryonic lethal.  
Colony maintenance Carrier x Noncarrier  
Health Report
Gene Details
Promoter No Data  
 1 Symbol Tg(Mt1-RET)304Ina  
Symbol name transgene insertion 304, Izumi Nakashima  
Chromosome UN  
Common name No Data  
Symbol description No Data  
 2 Symbol No Data  
Symbol name SV40 splicing signal-polyadenylation site  
Chromosome UN  
Common name No Data  
Symbol description No Data  
Promoter mouse metallothionein 1 promoter/enhancer  
 3 Symbol RET  
Symbol name recombinant RET proto-oncogene (human)  
Chromosome UN  
Common name RET51, RET9  
Symbol description No Data  
References EMBO J. 1991 Nov;10(11):3167-75.  
Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene.
Research applications Cancer Research,
Dermatology Research,
Mouse Models for Human Disease  
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR.  
Additional information
 1 Lab HP  
 2 Genotyping protocol <PCR>  
Depositor Kato, Masashi (Chubu University College of Life and Health Sciences)  Kato, Masashi 
Strain Status /
(Expected delivery)

back Back
RIKEN BioResource Research Center

English page click here ANIMAL SEARCH SYSTEM